STOCK TITAN

Structure Therapeutics Inc ADR - GPCR STOCK NEWS

Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.

Structure Therapeutics Inc (GPCR) is a clinical-stage biopharmaceutical company advancing oral small-molecule therapeutics targeting G-protein coupled receptors (GPCRs) for chronic metabolic and cardiopulmonary conditions. This page serves as the definitive source for verified corporate announcements and scientific developments.

Investors and industry observers will find timely updates on clinical trial milestones, regulatory progress, and strategic partnerships. The curated news collection enables tracking of the company's pipeline advancements in obesity, diabetes, and related disorders through structure-based drug discovery platforms.

All content undergoes strict verification to ensure accuracy, with updates spanning phase trial results, intellectual property developments, and manufacturing scalability achievements. Regular monitoring of this resource provides insights into GPCR's progress in creating alternatives to injectable biologic therapies.

Bookmark this page for streamlined access to essential updates about Structure Therapeutics' innovative approach to oral therapeutics development. Check back frequently to stay informed about new research breakthroughs and corporate initiatives.

Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) reported Q2 2024 financial results and recent highlights. Key points include:

1. GSBR-1290 Phase 2b obesity study on track for Q4 2024 initiation.

2. Oral small molecule amylin receptor agonist development candidate expected in Q4 2024.

3. Strong financial position with $927.1 million cash balance, funding operations through at least 2027.

4. Q2 2024 R&D expenses increased to $22.1 million from $19.4 million in Q2 2023.

5. Q2 2024 G&A expenses rose to $11.3 million from $6.6 million in Q2 2023.

6. Net loss for Q2 2024 was $26.0 million, compared to $23.3 million in Q2 2023.

7. GSBR-1290 Phase 2a results showed 6.2% placebo-adjusted mean weight loss at 12 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary

Structure Therapeutics (NASDAQ: GPCR) announced the closing of its upsized public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, at $52.50 per ADS. The offering, which included the full exercise of the underwriters' option to purchase an additional 1,360,045 ADSs, generated gross proceeds of around $547.4 million. The proceeds are subject to underwriting discounts, commissions, and offering expenses. The offering was managed by Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets. The registration statements for the securities became effective on June 5, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
-
Rhea-AI Summary

Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), announced the pricing of its upsized public offering. The company is set to offer 9,066,972 American Depositary Shares (ADS) at $52.50 each, aiming for gross proceeds of approximately $476 million before deductions. An additional 1,360,045 ADSs may be purchased by underwriters within 30 days. The offering, managed by major financial institutions including Goldman Sachs and Morgan Stanley, will close on June 7, 2024, contingent on standard conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
Rhea-AI Summary

Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), has filed a Form S-1 registration statement with the SEC for a proposed public offering of 8,000,000 American depositary shares (ADSs). Each ADS represents three ordinary shares. The company may also offer pre-funded warrants in lieu of ADSs. The price per pre-funded warrant will be the ADS price minus $0.0001. The underwriters have a 30-day option to purchase up to an additional 1,200,000 ADSs. The offering's completion depends on market conditions and other factors. Joint book-running managers include Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
-
Rhea-AI Summary

Structure Therapeutics announced positive topline data from its Phase 2a study and capsule to tablet PK study for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks, while the capsule to tablet PK study achieved up to a 6.9% weight loss. GSBR-1290 demonstrated favorable safety and tolerability with low discontinuation rates due to adverse events.

The company plans to start a 36-week Phase 2b study in the fourth quarter of 2024, following an IND submission to the FDA in the third quarter. The new study will use the tablet formulation and involve approximately 300 participants.

These results underscore the potential of GSBR-1290 as a treatment for obesity, with benefits including once-daily dosing and favorable safety profiles. Future development plans include exploring higher doses and combination therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.21%
Tags
-
Rhea-AI Summary

Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) CEO to participate in a fireside chat at Leerink Partners Global Biopharma Conference. The company is developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
conferences
-
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) reported financial results for Q4 and full year 2023, with a year-end cash balance of $467.3 million. The company highlighted successful Phase 2a data for GSBR-1290 in obesity and type 2 diabetes, with plans for Phase 2b trials. They also outlined upcoming milestones for other programs targeting metabolic and cardiopulmonary diseases. The company raised $485.0 million in equity capital in 2023, with strong financials to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
-
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) provided a development program update for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a data showed significant reductions in HbA1c and weight in type 2 diabetes mellitus patients and obesity cohorts. The drug demonstrated favorable safety, tolerability, and efficacy, with no treatment-related serious adverse events and a low study discontinuation rate. The company plans to initiate a Phase 2b study in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.82%
Tags
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) announced positive results from the Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, showing significant weight loss and an encouraging safety profile. They also highlighted upcoming milestones for GSBR-1290 in treating Type 2 Diabetes Mellitus (T2DM) and obesity, with topline data expected in December 2023 and first half of 2024, respectively. The company completed a $300 million financing, expected to fund operations through at least 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
Structure Therapeutics Inc ADR

Nasdaq:GPCR

GPCR Rankings

GPCR Stock Data

1.25B
52.74M
4.83%
110.46%
12.07%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO